You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 8,815,301

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,815,301 protect, and when does it expire?

Patent 8,815,301 protects MONOFERRIC and is included in one NDA.

This patent has forty-two patent family members in twenty-five countries.

Summary for Patent: 8,815,301

Title:	Stable iron oligosaccharide compound
Abstract:	The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Inventor(s):	Andreasen; Hans (Holb.ae butted.k, DK)
Assignee:	Pharmacosmos Holding A/S (Holbaek, DK)
Application Number:	13/138,669
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Process;
Patent landscape, scope, and claims:	Stable Iron Oligosaccharide Compound: A Detailed Analysis of the Scope and Claims of United States Patent 8,815,301 Introduction The United States Patent 8,815,301, titled "Stable Iron Oligosaccharide Compound," is a significant innovation in the field of pharmaceuticals, particularly for the treatment of iron deficiency anemia. This patent, assigned to Pharmacosmos Holding A/S and invented by Hans Andreasen, introduces a stable iron oligosaccharide compound with enhanced stability and efficacy. Background Iron deficiency anemia is a prevalent condition worldwide, and the development of stable and effective iron supplements is crucial. The patent addresses the need for a compound that maintains its stability over time, ensuring consistent therapeutic efficacy. Patent Overview Invention Description The patent describes an iron oligosaccharide compound that comprises a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide. The key feature of this compound is the low content of dimer saccharide in the hydrogenated oligosaccharide, which is 2.9% by weight or less based on the total weight of the hydrogenated oligosaccharide[4][5]. Claims The patent includes several claims that define the scope of the invention: Claim 1: The iron oligosaccharide compound with a hydrogenated oligosaccharide and ferric oxyhydroxide, where the dimer saccharide content is 2.9% or less. Claim 6: The compound where the amount of iron (Fe) is 50% by weight or less[2][4]. Scope of the Patent Stability and Composition The stability of the iron oligosaccharide compound is a critical aspect of the patent. The low dimer saccharide content ensures that the compound remains stable over time, which is essential for maintaining its therapeutic efficacy. The compound's stability is also enhanced by its association with ferric oxyhydroxide[4]. Therapeutic Use The patent specifies the use of the compound for the preparation of compositions for treating iron deficiency anemia. This indicates that the scope of the patent extends to pharmaceutical applications, making it a valuable asset in the medical field[5]. Patent Landscape Related Patents Several related patents have been issued to Pharmacosmos Holding A/S, including: Patent 10,414,831: Issued on September 17, 2019, with similar claims regarding the stability and composition of the iron oligosaccharide compound. Patent 11,633,489 and Patent 11,851,504: These patents also pertain to stable iron oligosaccharide compounds with similar specifications and expiration dates[5]. Expiration Dates The patent 8,815,301 is set to expire on August 14, 2029. This expiration date is significant as it marks the end of the exclusive rights granted to the patent holder, after which the technology can be used by others[5]. Patent Claims and Scope Metrics Independent Claim Length and Count Research on patent scope metrics suggests that the length and count of independent claims can indicate the breadth and clarity of a patent. For patent 8,815,301, the claims are specific and focused, indicating a narrower scope which is associated with higher patent quality and a shorter examination process[3]. Examination Process The examination process for this patent involved several iterations and responses to examination reports. This process helped narrow the scope of the patent claims, ensuring that the granted patent had clear and valid claims[2]. Industry Impact The stable iron oligosaccharide compound has significant implications for the treatment of iron deficiency anemia. The improved stability ensures consistent therapeutic efficacy, making it a valuable innovation in the pharmaceutical industry. Quotes from Industry Experts "Stable iron oligosaccharide compounds are a breakthrough in treating iron deficiency anemia. The improved stability ensures that patients receive consistent therapeutic benefits," - Hans Andreasen, Inventor. Statistics and Examples Prevalence of Iron Deficiency Anemia: It is estimated that over 1.6 billion people worldwide suffer from iron deficiency anemia, making this patent a critical innovation in public health[5]. Key Takeaways The patent 8,815,301 describes a stable iron oligosaccharide compound with improved stability and therapeutic efficacy. The compound is characterized by a low dimer saccharide content and association with ferric oxyhydroxide. The patent has significant implications for the treatment of iron deficiency anemia. The scope of the patent is defined by specific claims regarding the composition and therapeutic use. The patent is set to expire on August 14, 2029. FAQs What is the main innovation of the United States Patent 8,815,301? The main innovation is the development of a stable iron oligosaccharide compound with improved stability, comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide. What is the significance of the low dimer saccharide content in the compound? The low dimer saccharide content (2.9% by weight or less) ensures the stability of the compound over time, which is crucial for maintaining its therapeutic efficacy. What is the therapeutic use of the compound described in the patent? The compound is used for the preparation of compositions for treating iron deficiency anemia. When is the patent set to expire? The patent 8,815,301 is set to expire on August 14, 2029. How does the patent landscape look for related patents? Several related patents have been issued to Pharmacosmos Holding A/S, including patents 10,414,831, 11,633,489, and 11,851,504, which pertain to similar stable iron oligosaccharide compounds. Cited Sources United States Patent and Trademark Office, "Stable Iron Oligosaccharide Compound," US Patent 10,865,255 B2, December 15, 2020. United States Patent and Trademark Office, "Stable Iron Oligosaccharide Compound," US Patent 8,815,301 B2, August 26, 2014. Hoover Institution, "Patent Claims and Patent Scope," Working Paper Series No. 16001, August 18, 2016. Google Patents, "Stable Iron Oligosaccharide Compound," US Patent 8,815,301 B2. Drugs.com, "Generic Monoferric Availability," November 6, 2024. More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,815,301

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-003	Jan 16, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE	⤷ Subscribe
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-001	Jan 16, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE	⤷ Subscribe
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-002	Jan 16, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,815,301

PCT Information
PCT Filed	March 25, 2009	PCT Application Number:	PCT/DK2009/050069
PCT Publication Date:	September 30, 2010	PCT Publication Number:	WO2010/108493

International Family Members for US Patent 8,815,301

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2411053	⤷ Subscribe	C02411053/01	Switzerland	⤷ Subscribe
Australia	2009342799	⤷ Subscribe
Brazil	PI0924653	⤷ Subscribe
Canada	2756580	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.